Furthermore, combining other AD-associated biomarkers, including CSF Aβ, tau, and amyloid PET, with structural MRI may be an alternative way to distinguish AD from other disorders, including ophthalmological diseases [170]. Here, MAPT is linked to Alzheimer disease.